Hikma Pharmaceuticals PLC (HKMPF) Stock

About Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC is a global pharmaceutical firm engaged in the development, manufacturing, commercialization, and distribution of a wide array of medications, including its own branded products, licensed drugs, and generic formulations. These pharmaceutical offerings come in various forms, such as solids, semi-solids, liquids, and injectables. The company's operations are divided into three core segments: Injectables, which primarily supplies generic injectable medications to hospitals; Generics, focusing on oral and other non-injectable generic drugs for the retail market; and Branded, which provides both proprietary generics and in-licensed pharmaceuticals to retail consumers and healthcare institutions. Hikma's product portfolio addresses a broad spectrum of medical needs, spanning anti-infectives, cardiovascular health, central nervous system conditions, diabetes, oncology, pain management, and respiratory disorders. Founded in 1978 and based in London, United Kingdom, the company extends its reach across the UK, the United States, the Middle East, North Africa, Europe, and other international markets.

Hikma Pharmaceuticals PLC is headquartered in GB.

Hikma Pharmaceuticals PLC (HKMPF) stock trades at $20.37 with a market capitalization of $4.29B. The stock is valued at a price-to-earnings (P/E) ratio of 0.19, price-to-book of 1.78, price-to-sales of 1.32. Over the past 52 weeks the stock has ranged between $16.34 and $27.96, and currently trades 27.1% below its 52-week high. It pays a dividend yielding 4.71%.

On profitability, Hikma Pharmaceuticals PLC generates a return on equity (ROE) of 15.83%, above the typical market average, return on capital employed of 13.38%, an operating margin of 16.81%, a net profit margin of 12.00%.

Official website: www.hikma.com